Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.25B 3.74B 3.47B 3.19B 5.99B 410B 6.08B 41.26B 16.12B 201B 15.97B 15.62B 696B P/E 2026 *
63.2x
P/E 2027 * 31.8x
Enterprise Value 3.28B 2.88B 2.68B 2.46B 4.62B 316B 4.7B 31.85B 12.44B 155B 12.33B 12.06B 538B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.19x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week-2.97%
Current month-1.82%
1 month+6.34%
3 months+13.11%
6 months-7.45%
Current year-7.00%
1 week 24.23
Extreme 24.232
26.16
1 month 24.23
Extreme 24.232
27.31
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Sell

Controller/Auditor

-11,421 0.0067%
29/05/26
Baker Bros. Advisors LP
FreeCompany 101,260 0.0591%
29/05/26 Fiscal year

Director

41,529 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-2.97%+7.77%-17.26% 4.25B
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.21%+0.45%+49.73%+93.52% 24.95B
Weighted average by Cap. +0.47%+0.85%+74.08%+133.83%

Financials

2026 *2027 *
Net sales 1.24B 1.09B 1.01B 930M 1.75B 120B 1.78B 12.04B 4.7B 58.78B 4.66B 4.56B 203B 1.4B 1.23B 1.14B 1.05B 1.97B 135B 2B 13.58B 5.31B 66.31B 5.26B 5.14B 229B
Net income 67.44M 59.23M 55.08M 50.54M 94.97M 6.49B 96.43M 654M 256M 3.19B 253M 248M 11.04B 142M 125M 116M 106M 200M 13.66B 203M 1.38B 538M 6.72B 533M 521M 23.23B
Net Debt -970M -852M -792M -727M -1.37B -93.4B -1.39B -9.41B -3.68B -45.92B -3.64B -3.56B -159B -1.18B -1.04B -966M -887M -1.67B -114B -1.69B -11.48B -4.48B -56.01B -4.44B -4.35B -194B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
24/07/26 US$24.84 +0.04% 1,046,976
23/07/26 US$24.83 -0.52% 1,272,018
22/07/26 US$24.96 -1.85% 1,163,336
21/07/26 US$25.43 +1.36% 1,340,502
20/07/26 US$25.09 -1.99% 1,486,529
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
24.84USD
Average target price
32.80USD
Spread / Average Target
+32.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock